Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model

Oncolytic virotherapy (OVT) is now understood to be an immunotherapy that uses viral infection to liberate tumor antigens in an immunogenic context to promote the development of antitumor immune responses. The only currently FDA-approved oncolytic virotherapy, T-Vec, is a modified type 1 herpes simp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Virol
Main Authors: Uche, Ifeanyi Kingsley, Fowlkes, Natalie, Vu, Luan, Watanabe, Tatiane, Carossino, Mariano, Nabi, Rafiq, del Piero, Fabio, Rudd, Jared S., Kousoulas, Konstantin G., Rider, Paul J. F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2021
Assuntos:
Cellular Response to Infection
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7925097/
https://ncbi.nlm.nih.gov/pubmed/33177208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01359-20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados